cystic fibrosis transmembrane conductance regulator (505-511) has been researched along with alpha-aminopyridine in 2 studies
| Studies (cystic fibrosis transmembrane conductance regulator (505-511)) | Trials (cystic fibrosis transmembrane conductance regulator (505-511)) | Recent Studies (post-2010) (cystic fibrosis transmembrane conductance regulator (505-511)) | Studies (alpha-aminopyridine) | Trials (alpha-aminopyridine) | Recent Studies (post-2010) (alpha-aminopyridine) |
|---|---|---|---|---|---|
| 17 | 1 | 3 | 5,813 | 460 | 3,246 |
| Protein | Taxonomy | cystic fibrosis transmembrane conductance regulator (505-511) (IC50) | alpha-aminopyridine (IC50) |
|---|---|---|---|
| Botulinum neurotoxin type A | Clostridium botulinum | 1.8 | |
| Nitric oxide synthase, endothelial | Homo sapiens (human) | 2.8 | |
| Nitric oxide synthase, brain | Homo sapiens (human) | 6 | |
| Nitric oxide synthase, brain | Rattus norvegicus (Norway rat) | 9 | |
| Nitric oxide synthase, inducible | Homo sapiens (human) | 1.9 | |
| Phosphatidylinositol 4-kinase alpha | Homo sapiens (human) | 7.1 | |
| Phosphatidylinositol 4-kinase type 2-beta | Homo sapiens (human) | 7.1 | |
| Phosphatidylinositol 4-kinase type 2-alpha | Homo sapiens (human) | 7.1 | |
| Phosphatidylinositol 4-kinase beta | Homo sapiens (human) | 7.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bompadre, SG; Kopeikin, Z; Yang, HY; Yuksek, Z | 1 |
| Mayor, S | 1 |
2 other study(ies) available for cystic fibrosis transmembrane conductance regulator (505-511) and alpha-aminopyridine
| Article | Year |
|---|---|
Combined effects of VX-770 and VX-809 on several functional abnormalities of F508del-CFTR channels.
Topics: Adenosine Triphosphate; Aminophenols; Aminopyridines; Benzodioxoles; Carrier Proteins; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; In Vitro Techniques; Intracellular Signaling Peptides and Proteins; Patch-Clamp Techniques; Peptide Fragments; Quinolones | 2014 |
Drug combination that corrects deficient protein in cystic fibrosis improves lung function.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Therapy, Combination; Humans; Peptide Fragments; Quinolones; Randomized Controlled Trials as Topic; Respiratory Function Tests | 2015 |